IL161198A0 - Treatment and diagnosis of insulin resistant states - Google Patents
Treatment and diagnosis of insulin resistant statesInfo
- Publication number
- IL161198A0 IL161198A0 IL16119802A IL16119802A IL161198A0 IL 161198 A0 IL161198 A0 IL 161198A0 IL 16119802 A IL16119802 A IL 16119802A IL 16119802 A IL16119802 A IL 16119802A IL 161198 A0 IL161198 A0 IL 161198A0
- Authority
- IL
- Israel
- Prior art keywords
- diagnosis
- treatment
- insulin resistant
- resistant states
- states
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32994701P | 2001-10-15 | 2001-10-15 | |
PCT/US2002/032874 WO2003032810A2 (en) | 2001-10-15 | 2002-10-15 | Treatment and diagnosis of insulin resistant states |
Publications (1)
Publication Number | Publication Date |
---|---|
IL161198A0 true IL161198A0 (en) | 2004-08-31 |
Family
ID=23287695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16119802A IL161198A0 (en) | 2001-10-15 | 2002-10-15 | Treatment and diagnosis of insulin resistant states |
Country Status (17)
Country | Link |
---|---|
US (3) | US20030100504A1 (xx) |
JP (1) | JP2005506342A (xx) |
CN (1) | CN1571675A (xx) |
AT (1) | AT500646A1 (xx) |
CA (1) | CA2461818A1 (xx) |
CZ (1) | CZ2004564A3 (xx) |
DE (1) | DE10297331T5 (xx) |
DK (1) | DK200400777A (xx) |
ES (1) | ES2304072B1 (xx) |
FI (1) | FI20040531A (xx) |
GB (1) | GB2395903B (xx) |
HK (1) | HK1063280A1 (xx) |
IL (1) | IL161198A0 (xx) |
LU (1) | LU91070B1 (xx) |
MX (1) | MXPA04003536A (xx) |
SE (2) | SE528775C2 (xx) |
WO (1) | WO2003032810A2 (xx) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004030604D1 (de) * | 2003-10-29 | 2011-01-27 | Genzyme Corp | N-(5-adamantane-1-yl-methoxy-pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz |
WO2006010534A1 (en) * | 2004-07-28 | 2006-02-02 | F.Hoffmann-La Roche Ag | Dickkopf homolog 3 as target/marker of beta cell failure |
JP2008522607A (ja) * | 2004-12-09 | 2008-07-03 | ニューロ セラピューティクス エービー | Dickkopfsおよび神経発生に関係した物質および方法 |
JPWO2006073195A1 (ja) * | 2005-01-07 | 2008-06-12 | 敏一 吉川 | 糖尿病の予知・診断方法および糖尿病予知・診断用キット |
CN1963511B (zh) * | 2005-11-11 | 2014-09-24 | 上海市肿瘤研究所 | Dkk-1蛋白在癌症诊断中的应用 |
BRPI0908312A2 (pt) | 2008-05-05 | 2015-08-18 | Novimmune Sa | '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular'' |
MA33248B1 (fr) | 2009-04-01 | 2012-05-02 | Genentech Inc | Traitement de troubles résistant à l'insuline |
US10930382B2 (en) * | 2016-06-30 | 2021-02-23 | Novo Nordisk A/S | Systems and methods for analysis of insulin regimen adherence data |
CN115124424B (zh) * | 2022-06-01 | 2024-04-05 | 重庆市食品药品检验检测研究院 | 非诺贝特半抗原及其制备方法、非诺贝特抗原、抗体及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187991B1 (en) * | 1995-05-23 | 2001-02-13 | Pfizer Inc | Transgenic animal models for type II diabetes mellitus |
-
2002
- 2002-10-15 CA CA002461818A patent/CA2461818A1/en not_active Abandoned
- 2002-10-15 DE DE10297331T patent/DE10297331T5/de not_active Withdrawn
- 2002-10-15 CZ CZ2004564A patent/CZ2004564A3/cs unknown
- 2002-10-15 LU LU91070A patent/LU91070B1/en active
- 2002-10-15 IL IL16119802A patent/IL161198A0/xx unknown
- 2002-10-15 JP JP2003535620A patent/JP2005506342A/ja not_active Withdrawn
- 2002-10-15 CN CNA028204034A patent/CN1571675A/zh active Pending
- 2002-10-15 AT AT0924302A patent/AT500646A1/de not_active Application Discontinuation
- 2002-10-15 GB GB0407486A patent/GB2395903B/en not_active Expired - Fee Related
- 2002-10-15 MX MXPA04003536A patent/MXPA04003536A/es not_active Application Discontinuation
- 2002-10-15 ES ES200450027A patent/ES2304072B1/es not_active Withdrawn - After Issue
- 2002-10-15 WO PCT/US2002/032874 patent/WO2003032810A2/en not_active Application Discontinuation
- 2002-10-15 US US10/271,628 patent/US20030100504A1/en not_active Abandoned
-
2004
- 2004-04-14 SE SE0400961A patent/SE528775C2/sv not_active IP Right Cessation
- 2004-04-14 FI FI20040531A patent/FI20040531A/fi not_active IP Right Cessation
- 2004-05-14 DK DK200400777A patent/DK200400777A/da not_active Application Discontinuation
- 2004-08-12 HK HK04106068A patent/HK1063280A1/xx not_active IP Right Cessation
-
2005
- 2005-02-11 US US11/056,562 patent/US20050170440A1/en not_active Abandoned
-
2006
- 2006-08-21 US US11/465,956 patent/US20060293239A1/en not_active Abandoned
- 2006-11-27 SE SE0602516A patent/SE0602516L/sv not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CZ2004564A3 (cs) | 2005-03-16 |
AT500646A1 (de) | 2006-02-15 |
GB2395903B (en) | 2005-08-31 |
CN1571675A (zh) | 2005-01-26 |
LU91070B1 (en) | 2004-04-15 |
DE10297331T5 (de) | 2004-11-18 |
JP2005506342A (ja) | 2005-03-03 |
SE0602516L (sv) | 2006-11-27 |
MXPA04003536A (es) | 2004-07-23 |
DK200400777A (da) | 2004-05-14 |
CA2461818A1 (en) | 2003-04-24 |
GB0407486D0 (en) | 2004-05-05 |
US20030100504A1 (en) | 2003-05-29 |
HK1063280A1 (en) | 2004-12-24 |
WO2003032810A3 (en) | 2004-06-17 |
FI20040531A (fi) | 2004-04-14 |
WO2003032810A2 (en) | 2003-04-24 |
SE0400961L (sv) | 2004-04-14 |
US20060293239A1 (en) | 2006-12-28 |
US20050170440A1 (en) | 2005-08-04 |
ES2304072A1 (es) | 2008-09-01 |
GB2395903A (en) | 2004-06-09 |
SE528775C2 (sv) | 2007-02-13 |
ES2304072B1 (es) | 2009-07-07 |
SE0400961D0 (sv) | 2004-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL158469A0 (en) | Diagnosis, treatment, and research of mental disorder | |
HUP0401127A3 (en) | Treatment and diagnosis of macrophage disease | |
AU2002367535A8 (en) | Diagnosis and treatment of vascular disease | |
AU2003290548A8 (en) | Prevention and treatment of synucleinopathic disease | |
AU2002303295B2 (en) | Diagnosis and treatment of neural disease and injury using microvoltammetry | |
AU2002225219A1 (en) | Diagnosis and treatment of multiple sclerosis | |
PL1623228T3 (pl) | APOCIII i leczenie oraz diagnozowanie cukrzycy | |
AU2002326813A1 (en) | Diagnosis and treatment of vascular disease | |
AU2003268295A8 (en) | "diagnosis and treatment of infertility" | |
LU91070B1 (en) | Treatment and diagnosis of insulin resistant states | |
HUP0303306A3 (en) | Use of il-18 inhibitors for the treatment and/or prevention of heart disease | |
AU2002341880A1 (en) | Diagnosis and treatment of vascular disease | |
AU2002341604A1 (en) | Diagnosis and treatment of vascular disease | |
EP1435962A4 (en) | TREATMENT OF DIABETES TYPE I | |
AU2003231279A8 (en) | Prevention and treatment of type 2 diabetes | |
EP1409734A4 (en) | DIAGNOSIS AND TREATMENT OF CANCER | |
GB2381272B (en) | Diagnosis and treatment of atherosclerosis | |
GB0101146D0 (en) | Treatment of skin conditions | |
GB9908059D0 (en) | Diagnosis and treatment of diseases | |
AU2002319591A1 (en) | Diagnosis and treatment of vascular disease | |
EP1461351A4 (en) | METHOD AND REAGENT FOR DIABETES DIAGNOSIS AND TREATMENT | |
GB0212790D0 (en) | Medicament for the treatment of diabetes | |
AU2001253024A1 (en) | Diagnosis and treatment of gastrointestinal disease | |
AU2002240745A1 (en) | Diagnosis and treatment of blood disorders | |
GB0316940D0 (en) | Treatment of skin and other medical conditions |